REPRODUCTIVE HORMONES & THE FERTILITY AXIS / COLOPHON
About This Reference Desk
An independent, citation-anchored digest of the reproductive-peptide literature. Not a vendor. Not a clinic. Not medical advice.
What Aubrie Peptides is
Aubrie Peptides is an independent editorial reference desk covering the published research on two peptides studied for reproductive hormones and the fertility axis: kisspeptin and PT-141 (bremelanotide), with kisspeptin as the lead. The site exists to make a technically demanding, clinically complex, and frequently misrepresented literature legible — to tell a reader, in plain language and with citations, what each compound was actually studied for, in which populations, and how far that evidence reaches.
The organizing idea is the frame: reproductive hormones and the fertility axis, plainly explained. Kisspeptin works upstream on the HPG axis — the body's hormonal pulse generator. PT-141 works downstream, in the neural circuits of desire. Together they cover the biology of sexual and reproductive health from two complementary angles. Each compound has its own page, a comparison page lines them up side by side, and a single shared references list aggregates every source.
The topics here — libido, arousal, reproductive hormones, sexual desire — are covered frankly and with the depth the research deserves. Community-reported effects are included, clearly labeled as anecdotal and not clinical evidence, because they are part of the honest picture. What we never do is recommend, prescribe, suggest a dose, or imply that any compound here is appropriate for self-administration.
Editorial method
Every claim on this site is keyed to a specific, numbered citation in the shared references list. Citations were selected from peer-reviewed journals (PubMed-indexed), systematic reviews, and official regulatory documents (prescribing information) — no secondary sources, no press releases, no vendor claims. Where a finding is preclinical (animal or cell data), that is stated explicitly alongside the species and model. Where human data exist, the study design, population, and sample size are noted, because a Phase 2 study of 60 women and a Phase 3 program of 1,267 women support very different levels of confidence.
The references index is reproduced in full on the references page, with DOI and PubMed links. Every cited number in the text maps to that index. Where the evidence is thin, preliminary, contested, or not yet replicated at scale, we say so — not as a disclaimer, but as part of the record itself. Where community anecdote is included (real-world reported effects), it is presented separately from study-attributed findings and explicitly identified as anecdotal, not clinical evidence.
No author biographies, credentials, or affiliations are fabricated on this site. The site is an editorial digest; its quality standard is the accuracy and completeness of its citation trail.
What this site is not
Aubrie Peptides is not a vendor, not a pharmacy, and not a clinic. It does not sell compounds, recommend suppliers, or provide medical advice. It does not list human doses. It does not suggest that any compound here is appropriate for self-administration outside a supervised research or medical setting.
The compounds covered here vary significantly in their regulatory and safety profiles: PT-141 (bremelanotide) is a prescription-only pharmaceutical in its approved indication [12]; kisspeptin is entirely investigational with no approved indication [2]. Neither this fact nor any content on this site constitutes a medical recommendation. Readers with clinical questions about reproductive health, low sexual desire, fertility, or hormonal conditions should consult a licensed healthcare provider — not a literature digest.
Contact: editorial@aubriepeptides.com